var data={"title":"Cyproheptadine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyproheptadine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5962?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyproheptadine-drug-information\" class=\"drug drug_general\">see &quot;Cyproheptadine: Drug information&quot;</a> and <a href=\"topic.htm?path=cyproheptadine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyproheptadine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14959840\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Euro-Cyproheptadine;</li>\n      <li>PMS-Cyproheptadine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057570\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihistamine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057564\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cyproheptadine-drug-information\" class=\"drug drug_general\">see &quot;Cyproheptadine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic conditions:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> Weight-directed or BSA-directed dosing: Children &ge;2 years and Adolescents: 0.25 mg/kg/day or 8 mg/m<sup>2</sup>/day in 2 to 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed-dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to 6 years: 2 mg every 8 to 12 hours; maximum daily dose: 12 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">7 to 14 years: 4 mg every 8 to 12 hours; maximum daily dose: 16 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;15 years: Initial: 4 mg every 8 hours; titrate to effect; usual range: 12 to 16 mg/day although some patients may require up to 32 mg; maximum daily dose: 0.5 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appetite stimulation:</b> Limited data available; dosing regimens variable; Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children &ge;2 years and Adolescents: 0.25 mg/kg/day divided twice daily; age-dependent maximum daily dose: &le;6 years: 12 mg/<b>day</b>; 7 to 14 years: 16 mg/<b>day</b>; &ge;15 years: 32 mg/<b>day</b>. Dosing based on an open-label trial of 66 pediatric cancer patients (median age: 11.7 years; range: 3 to 19 years) which reported 76% response rate (either weight gained or stabilized); mean weight gain: 2.6 kg (range: -0.1 to 10 kg); in a subset analysis, patients &gt;9 years showed a greater response than younger patients as did patients with hematologic malignancies (Couluris 2008).  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: Children &ge;5 years and Adolescents: Initial: 2 mg every 6 hours (4 times daily) for 1 week; if tolerated, increase dose to 4 mg every 6 hours; dosing based on a short-term (12-week) double-blind, placebo-controlled trial (n=8 treatment group) and a long-term (1-year) open-label trial (n=12) in cystic fibrosis patients; results showed significant increases in weight gain (3.4 kg vs 1.1 kg in placebo); long-term results showed a generally sustained effect (eg, no further weight loss or some additional weight gain) over study duration (Homnick 2004; Homnick 2005). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyclic vomiting syndrome; prevention:</b> Limited data available: Oral: Children 2 to 5 years: 0.25 to 0.5 mg/kg/day in divided doses 2 to 3 times daily; maximum daily dose: 12 mg/<b>day</b>; some clinicians have used once daily dose at bedtime to prevent day time sedation (Andersen 1997; Li 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dyspeptic syndrome; refractory:</b> Limited data available: Oral: Infants &ge;9 months and Children &lt;12 years: Reported range: 0.04 to 0.6 mg/kg/day in divided doses 2 to 3 times daily; median effective dose: 0.22 mg/kg/day; dosing based on a retrospective, open-label trial of 80 pediatric patients (median age: 9.8 years; range: 9 months to 20 years) with dyspeptic symptoms (eg, nausea, early satiety, abdominal pain, retching after fundoplication and vomiting) which failed to respond to conventional therapy (eg, diet changes, H<sub>2</sub>-blockers, proton pump inhibitors); observed response rate was 55%; a higher response rate (86%) was seen with retching post-Nissen fundoplication (Rodriguez 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Migraine; prophylaxis:</b> Limited data available: Oral: Children &ge;3 years and Adolescents: 0.2 to 0.4 mg/kg/day divided twice daily; reported daily dose range: 2 to 8 mg/<b>day</b>; maximum daily dose: 0.5 mg/kg/<b>day</b>; experience suggests younger patients more tolerant of common cyproheptadine side effects (ie, sedation and increased appetite) (Lewis 2004; Lewis 2004a) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Spasticity associated with spinal cord damage:</b> Limited data available; efficacy results variable: Oral: Children &ge;12 years and Adolescents: 4 mg at bedtime; increase by a 4 mg dose every 3 to 4 days; mean daily dose: 16 mg/day in divided doses; maximum daily dose: 36 mg/<b>day</b> (Gracie 1997).  In the most rigorous evaluation, a double-blind, placebo-controlled, crossover trial of 16 hemiplegic pediatric patients (age range: 4 to 18 years), cyproheptadine (relatively low dose: 1 to 2 mg/day) had no statistical evidence of an effect on gait nor improvement in spasticity parameters (Khodadadeh 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Allergic conditions:</b> Oral: 4 to 20 mg/day divided every 8 hours (not to exceed 0.5 mg/kg/day); some patients may require up to 32 mg/day for adequate control of symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; however, elimination is diminished in renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155692\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/5 mL (10 mL [DSC], 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155678\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057574\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Usually administered in 2-4 divided doses (eg, every 6-12 hours); for some uses (eg, cyclic vomiting syndrome), once daily administration at bedtime has been used for some indications to improve tolerability of sedative effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25188839\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral syrup: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057573\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Perennial and seasonal allergic rhinitis and other allergic symptoms including cold urticaria (FDA approved in ages &ge;2 years and adults); has also been used to promote weight gain by appetite stimulation in various disease states (eg, cystic fibrosis, cancer-related cachexia); migraine prophylaxis; prevention of episodes of cyclic vomiting; management of dyspeptic symptoms; treatment of  spasticity associated with spinal cord damage; and management of serotonin syndrome (eg, following acute SSRI ingestions)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155758\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cyproheptadine may be confused with cyclobenzaprine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Periactin may be confused with Percodan, Persantine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Cyproheptadine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Cyproheptadine is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM)  performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Periactin brand name for cyproheptadine [US, multiple international markets] may be confused with Perative brand name for an enteral nutrition preparation [multiple international markets] and brand name for ketoconazole [Argentina]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155756\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Extrasystoles, hypotension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Ataxia, chills, confusion, dizziness, drowsiness, euphoria, excitement, fatigue, hallucination, headache, hysteria, insomnia, irritability, nervousness, neuritis, paresthesia, restlessness, sedation, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, skin photosensitivity, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, cholestasis, constipation, diarrhea, increased appetite, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Difficulty in micturition, urinary frequency, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic:  Agranulocytosis, hemolytic anemia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatic failure, hepatitis, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylactic shock, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Labyrinthitis (acute), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Nasal congestion, pharyngitis, thickening of bronchial secretions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155697\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Use in newborn or premature infants or breast-feeding mothers; hypersensitivity to cyproheptadine or any component of the formulation; monoamine oxidase inhibitor therapy; angle-closure glaucoma; stenosing peptic ulcer; symptomatic prostatic hypertrophy; bladder neck obstruction; pyloroduodenal obstruction; elderly, debilitated patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155682\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Antihistamines may cause excitation in young children. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855542\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Excessive dosages of antihistamine in infants and young children may cause hallucinations, CNS depression, seizures, and death. Use with caution and use the lowest effective dose in children &ge;2 years of age and avoid concomitant use with other medications having respiratory depressant effects.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299111\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155687\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13194&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the sedative effect of Antihistamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Cyproheptadine may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155689\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14389393\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Per the product labeling, an increased risk of congenital abnormalities was not observed following maternal use of cyproheptadine during the first, second, or third trimesters in two studies of pregnant women; however the possibility of harm cannot be ruled out. Although cyproheptadine is approved for the treatment of allergic conditions such as rhinitis and uritcaria, other agents are preferred for use in pregnant women (Scadding 2008; Wallace 2008; Zuberbier 2014). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy (Ambros-Rudolph 2011; Kremer 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155681\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A potent antihistamine and serotonin antagonist with anticholinergic effects; competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract (Paton 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155696\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed (Graudins 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily by hepatic glucuronidation (Hintze 1975) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Metabolites: ~16 hours (Paton 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 6 to 9 hours (Paton 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~40% primarily as metabolites); feces (2% to 20%, &lt;6% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323084\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Cyproheptadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/5 mL (473 mL): $64.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cyproheptadine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $106.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155701\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adekin (GR);</li>\n      <li>Antisemin (TW);</li>\n      <li>Apetamin-P (LK);</li>\n      <li>Apeton 4 (ID);</li>\n      <li>Cipla-Actin (ZA);</li>\n      <li>Ciplactin (IN, VN);</li>\n      <li>Ciprogal (UY);</li>\n      <li>Ciproral (DE);</li>\n      <li>Ciprovit-A (PE);</li>\n      <li>Ciptadine (JO, QA);</li>\n      <li>Cyheptine (TH);</li>\n      <li>Cypon Plain (LK);</li>\n      <li>Cyprodin (TW);</li>\n      <li>Cyprogin (TH);</li>\n      <li>Cypromin (JP, TW);</li>\n      <li>Cyprono (TH);</li>\n      <li>Cyprosian (TH);</li>\n      <li>Cyprotin (SG);</li>\n      <li>Cyprotol (BG);</li>\n      <li>Cytadine (TW);</li>\n      <li>Ennamax (ID);</li>\n      <li>Glocyp (ID);</li>\n      <li>Gubamine (AR);</li>\n      <li>Heptasan (ID);</li>\n      <li>Heptin (LK);</li>\n      <li>Istam-Far (GR);</li>\n      <li>Klarivitina (ES);</li>\n      <li>Kulinet (GR);</li>\n      <li>Pangavit Pedi&aacute;trico (MX);</li>\n      <li>Periactin (AE, AT, AU, BE, BF, BH, BJ, CH, CI, CO, CY, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, OM, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TH, TN, TR, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Periactine (FR);</li>\n      <li>Peritol (BB, BM, BS, BZ, CZ, DE, GY, HN, HU, IN, JM, LK, PL, PR, RO, RU, SK, SR, TT, VN);</li>\n      <li>Perytol (UA);</li>\n      <li>Petina (MY);</li>\n      <li>Pilian (MY, TW);</li>\n      <li>Poncohist (ID);</li>\n      <li>Prakten (TR);</li>\n      <li>Prohessen (ID);</li>\n      <li>Pronicy (ID);</li>\n      <li>Showmin (TW);</li>\n      <li>Triactin (QA);</li>\n      <li>Trimetabol (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ambros-Rudolph CM, &quot;Dermatoses of Pregnancy - Clues to Diagnosis, Fetal Risk and Therapy,&quot; <i>Ann Dermatol</i>, 2011, 23(3):265-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersen JM, Sugerman KS, Lockhart JR, et al, &quot;Effective Prophylactic Therapy for Cyclic Vomiting Syndrome in Children Using Amitriptyline or Cyproheptadine,&quot; <i>Pediatrics</i>, 1997, 100(6):977-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/9374568/pubmed\" target=\"_blank\" id=\"9374568\">9374568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couluris M, Mayer JL, Freyer DR, et al, &quot;The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment-Related Cachexia,&quot; <i>J Pediatr Hematol Oncol</i>, 2008, 30(11):791-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18989154/pubmed\" target=\"_blank\" id=\"18989154\">18989154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracies JM, Nance P, Elovic E, et al, &ldquo;Traditional Pharmacological Treatments for Spasticity. Part II: General and Regional Treatments,&rdquo; <i>Muscle Nerve Suppl</i>, 1997, 6:S92-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/9826984 /pubmed\" target=\"_blank\" id=\"9826984 \">9826984 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Homnick DN, Homnick BD, Reeves AJ, et al, &quot;Cyproheptadine Is an Effective Appetite Stimulant in Cystic Fibrosis,&quot; <i> Pediatr Pulmonol</i>, 2004, 38(2):129-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15211696/pubmed\" target=\"_blank\" id=\"15211696\">15211696</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Homnick DN, Marks JH, Hare KL, et al, &quot;Long-Term trial of Cyproheptadine as an Appetite Stimulant in Cystic Fibrosis,&quot; <i>Pediatr Pulmonol</i>, 2005, 40(3):251-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/16015665/pubmed\" target=\"_blank\" id=\"16015665\">16015665</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khodadadeh S, Holstein H, Purushothaman S, et al, &quot;A Study of the Effect of Cyproheptadine on Gait in Hemiplegic Children,&quot; <i>Gait Posture</i>, 1998, 8(3):205-213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/10200409/pubmed\" target=\"_blank\" id=\"10200409\">10200409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. <i>Dig Dis</i>. 2014;32(5):637-645.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/25034299/pubmed\" target=\"_blank\" id=\"25034299\">25034299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis D, Ashwal S, Hershey A, et al, &quot;Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society,&quot; <i>Neurology</i>, 2004, 63(12):2215-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15623677/pubmed\" target=\"_blank\" id=\"15623677\">15623677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis DW, Diamond S, Scott D, et al, &quot;Prophylactic Treatment of Pediatric Migraine,&quot; <i>Headache</i>, 2004, 44(3):230-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/15012660/pubmed\" target=\"_blank\" id=\"15012660\">15012660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li BU, Lefevre F, Chelimsky GG, et al, &quot;North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2008, 47(3):379-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18728540/pubmed\" target=\"_blank\" id=\"18728540\">18728540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messinis IE, Souvatzoglou A, Fais N, et al, &quot;Histamine H1 Receptor Participation in the Control of Prolactin Secretion in Postpartum,&quot; <i>J Endocrinol Invest</i>, 1985, 8(2):143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/3928731/pubmed\" target=\"_blank\" id=\"3928731\">3928731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paton DM and Webster DR, &quot;Clinical Pharmacokinetics of H1-Receptor Antagonists (The Antihistamines),&quot;  <i>Clin Pharmacokinet</i>, 1985, 10(6):477-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/2866055/pubmed\" target=\"_blank\" id=\"2866055\">2866055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez L, Diaz J, and Nurko S, &quot;Safety and Efficacy of Cyproheptadine for Treating Dyspeptic Symptoms in Children,&quot; <i>J Pediatr</i>, 2013, Feb 16.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scadding GK, Durham SR, Mirakian R, et al. British Society for Allergy and Clinical Immunology. BSACI guidelines for the management of allergic and non-allergic rhinitis. <i>Clin Exp Allergy</i>. 2008;38(1):19-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18081563/pubmed\" target=\"_blank\" id=\"18081563\">18081563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wainberg M, Barbeau H, and Gauthier S, &ldquo;The Effects of Cyproheptadine on Locomotion and on Spasticity in Patients With Spinal Cord Injuries,&rdquo; <i>J Neurol Neurosurg Psychiatry</i>, 1990, 53(9):754-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/2246657/pubmed\" target=\"_blank\" id=\"2246657\">2246657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker RB and Kanfer I, &quot;Pharmacokinetics of Cyclizine Following Intravenous Administration to Human Volunteers,&quot; <i>Eur J Pharm Sci</i>, 1996, 4(5):301-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wians FH, Norton JT, and Wirebaugh, &ldquo;False-Positive Serum Tricyclic Antidepressant Screen With Cyproheptadine,&rdquo; <i>Clin Chem</i>, 1993, 39(6):1355-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/8504557/pubmed\" target=\"_blank\" id=\"8504557\">8504557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.<i>Allergy</i>. 2014;69(7):868-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproheptadine-pediatric-drug-information/abstract-text/24785199/pubmed\" target=\"_blank\" id=\"24785199\">24785199</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13194 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14959840\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057570\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057564\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155692\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F155678\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057574\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25188839\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057573\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F155758\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155756\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155697\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155682\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855542\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299111\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F155687\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F155689\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14389393\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155681\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F155696\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323084\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155701\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13194|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyproheptadine-drug-information\" class=\"drug drug_general\">Cyproheptadine: Drug information</a></li><li><a href=\"topic.htm?path=cyproheptadine-patient-drug-information\" class=\"drug drug_patient\">Cyproheptadine: Patient drug information</a></li></ul></div></div>","javascript":null}